Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
Public ClinicalTrials.gov record NCT02047734. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record. The primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of clinical relapses at the end of Month 24 in patients with relapsing multiple sclerosis (RMS).
Study identification
- NCT ID
- NCT02047734
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,320 participants
Conditions and interventions
Conditions
Interventions
- Ozanimod Drug
- Ozanimod placebo Drug
- Interferon beta-1a Drug
- Interferon beta-1a placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 3, 2013 (Actual)
- Primary completion
- Mar 27, 2017 (Actual)
- Completion
- Apr 13, 2017 (Actual)
- Last update posted
- Feb 11, 2021
2013 – 2017
United States locations
- U.S. sites
- 35
- U.S. states
- 11
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Receptos Study Site 115 | Phoenix | Arizona | 85004 | — |
| Xenoscience | Phoenix | Arizona | 85004 | — |
| Receptos Study Site 118 | Phoenix | Arizona | 85013 | — |
| Saint Josephs Hosptial and Medical Center | Phoenix | Arizona | 85013 | — |
| Territory Neurology and Research Institute | Tucson | Arizona | 85704 | — |
| Receptos Study Site 119 | Tucson | Arizona | 85741 | — |
| Alta Bates Summit Medical Center | Berkeley | California | 94705 | — |
| Receptos Study Site 110 | Berkeley | California | 94705 | — |
| Receptos Study Site 122 | Long Beach | California | 90806 | — |
| Receptos Study Site 112 | Sacramento | California | 95817 | — |
| University of California Davis Medical Center | Sacramento | California | 95817 | — |
| Multiple Sclerosis Center at UCSF | San Francisco | California | 94158 | — |
| Receptos Study Site 120 | San Francisco | California | 94158 | — |
| Denver Neurological Research LLC | Denver | Colorado | 80210 | — |
| Receptos Study Site 127 | Denver | Colorado | 80210 | — |
| Neurology Associates PA | Maitland | Florida | 32751 | — |
| Receptos Study Site 114 | Maitland | Florida | 32751 | — |
| Receptos Study Site 124 | Pompano Beach | Florida | 33060 | — |
| Neurostudies Inc | Port Charlotte | Florida | 33952 | — |
| Receptos Study Site 123 | Port Charlotte | Florida | 33952 | — |
| Infinity Clinical Research LLC | Sunrise | Florida | 33351 | — |
| West Georgia Sleep Disorder Center and Neurology Associates | Douglasville | Georgia | 30134 | — |
| Consultants In Neurology | Northbrook | Illinois | 60062 | — |
| Receptos Study Site 113 | Northbrook | Illinois | 60062 | — |
| Receptos Study Site 121 | St Louis | Missouri | 63110 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Receptos Study Site 101 | Charlotte | North Carolina | 28204 | — |
| The Neurological Institute PA | Charlotte | North Carolina | 28204 | — |
| Neurology and Neuroscience Associates Inc. | Akron | Ohio | 44320 | — |
| Receptos Study Site 107 | Akron | Ohio | 44320 | — |
| Receptos Study Site 104 | Cleveland | Ohio | 44195 | — |
| Receptos Study Site 109 | Philadelphia | Pennsylvania | 19104 | — |
| Receptos Study Site 102 | Seattle | Washington | 98104 | — |
| The Polyclinic | Seattle | Washington | 98104 | — |
| Receptos Study Site 125 | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 264 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02047734, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 11, 2021 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02047734 live on ClinicalTrials.gov.